A5001646287- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Nausea and vomiting management
- Diverse Scientific Research Studies
- Urticaria and Related Conditions
- Innovations in Medical Education
- Sarcoidosis and Beryllium Toxicity Research
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Advanced Breast Cancer Therapies
- Diabetic Foot Ulcer Assessment and Management
- Drug-Induced Adverse Reactions
- Pancreatic and Hepatic Oncology Research
- Reflective Practices in Education
- Higher Education Practises and Engagement
- Problem and Project Based Learning
- Cerebral Palsy and Movement Disorders
- Brain Metastases and Treatment
- Developmental Biology and Gene Regulation
- Case Reports on Hematomas
- Invertebrate Immune Response Mechanisms
- Body Composition Measurement Techniques
George Washington University Hospital
2023
NorthShore University HealthSystem
2016-2020
AEgis Technologies (United States)
2020
Quinnipiac University
2018
University of Central Florida
2017
Florida College
2017
University of Southampton
2015-2016
Columbia University
2015
JSS Academy of Higher Education and Research
2014
Texas Oncology
2007
Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus (BCP) in chemotherapy-naïve nonsquamous non-small-cell lung cancer (NSCLC). We present safety patient-reported outcomes (PROs) to provide additional information on the relative impact of adding atezolizumab chemotherapy with without bevacizumab NSCLC.Patients were randomly assigned receive atezolizumab, (ACP), ABCP, or BCP. Coprimary end points overall investigator-assessed progression-free...
To determine the exposure-response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) urothelial carcinoma (UC) to identify alternative dosing regimens.ER analyses were conducted using pooled NSCLC UC data from phase 1 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, NCT02302807, respectively). Objective response rate, overall survival, adverse events evaluated vs...
Background Atezolizumab treatment improves survival, with manageable safety, in patients previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL ( NCT03285763 ) was conducted to evaluate the safety and efficacy of atezolizumab monotherapy a clinically diverse population cancer, including those not eligible for pivotal trials. Methods Patients stage IIIB/IV cancer whose disease progressed after 1–2 lines chemotherapy were this open-label,...
Demonstrate the safety and efficacy of a standardized intravenous etomidate infusion protocol in normalizing cortisol levels patients with severe life-threatening hypercortisolism.A retrospective case series seven representing nine episodes hypercortisolism at two large academic medical centers was conducted. Patients were included this if they received an for treatment hypercortisolism. The administered via newly developed designed to safely reduce until more long-term or definitive...
Purpose This study aims to evaluate the effectiveness of virtual reality (VR) training in enhancing paramedics' preparedness and response skills mass casualty incidents (MCIs). Design was an observational registered paramedics intensive care paramedic students from NSW Ambulance. Participants completed a 30-minute VR session simulating car crash MCI scenario, plus pre- post-intervention surveys measuring gaming literacy, prior simulation experience perceived improvements skills. Findings...
Purpose This study evaluates the impact of multidisciplinary learning on confidence, preparedness, and collaborative skills healthcare emergency service professionals during a field training exercise. It aimed to assess improvements in communication, teamwork, decision-making skills, as well identify areas for further training. Design Conducted at Charmhaven Rural Fire Service (RFS) Control Centre August 2024, exercise involved NSW Ambulance, RFS, Volunteer Rescue Association, Central Coast...
9002 Background: PD-L1/PD-1 inhibitors have transformed the treatment (tx) of advanced NSCLC. Evidence suggests that occurrence irAEs with these agents may predict improved outcomes in cancers such as Atezolizumab (atezo; anti–PD-L1) has shown efficacy and tolerability NSCLC is currently approved 1L 2L+ settings. The Ph 3 IMpower130, IMpower132 IMpower150 trials evaluated atezo + chemo ± bevacizumab (bev) tx We explore association between trials. Methods: Each trial enrolled tx-naive...
<h3>Importance</h3> Checkpoint inhibition in cancer immunotherapy related to T-cell–driven mechanisms of action associated with acute macular neuroretinopathy (AMN) and diffuse retinal venulitis, an adverse event not previously described, is reported here. <h3>Objective</h3> To describe 2 patients who developed ophthalmologic events after treatment the programmed death 1 axis inhibitor, atezolizumab. <h3>Design, Setting, Participants</h3> Retrospective review treated atezolizumab for...
Epiploic appendages are normal pedunculated peritoneal fat containing outpouchings bordering tenia coli on the anti-mesenteric surface of colon, extending from caecum to rectosigmoid. Functions currently unknown, though some postulate them a blood reservoir. The epiploic can become inflamed, with clinical presentations mimicking that diverticulitis or acute appendicitis. However, unlike appendicitis, appendagitis treated conservatively antibiotics. Currently, estimated rate correct...
4616 Background: Talabostat is an oral small molecule inhibitor of fibroblast activation protein (FAP), a stromal enzyme with collagenase and dipeptidyl peptidase activity. also upregulates cytokine chemokine production, resulting in immune stimulation. active pancreatic tumor xenograft models enhances the activity gemcitabine mice. Therefore, clinical trial patients metastatic cancer was initiated. Methods: Open-label, single-arm, Phase 2 study 60 evaluable Stage IV cancer. Study treatment...
e21623 Background: IMpower110 evaluated atezo mono in PD-L1–selected, chemo-naive patients (pts) with nonsquamous (nsq) or squamous (sq) NSCLC. At the interim analysis, met its primary OS endpoint, a statistically significant and clinically meaningful improvement for vs chemo TC3 IC3 wild-type ( EGFR/ALK-negative) pts. We report on safety profile of IMpower110. Methods: 572 pts stage IV nsq sq NSCLC, PD-L1 expression ≥ 1% TC IC ECOG PS 0-1 were randomized 1:1 to receive (1200 mg q3w) (4 6...
Abstract Objective Previously published studies indicate that a pre‐populated default quantity may decrease opioid amounts on discharge prescriptions from the emergency department (ED). However, longitudinal effect of defaulted quantities has not been described in literature. Methods A retrospective review electronic health record data visits to 4 hospital EDs community system examined prescription dispense 3.5 years pre‐ and 6.5 post‐implementation seventeen. The primary purpose was...
Immune-related pneumonitis is an important toxicity associated with checkpoint inhibitor therapy anti-PD-1 or anti-PD-L1 antibodies, often necessitating discontinuation of treatment. Development methods to mitigate inhibitor-related required.The contributions PD-L1, PD-L2, and VEGF the pathogenesis were examined in IL2- plus IL18-induced mouse model (IL model). Furthermore, incidences retrospectively patients non-small cell lung cancer treated mAb atezolizumab chemotherapy, without anti-VEGF...
3557 Background: The RAS/MAPK pathway (including BRAF) is dysregulated in a broad range of cancers including CRC, resulting downstream activation ERK1/2. Metastatic CRC with BRAF V600E mutation (BRAF mCRC) has dramatically worse survival than non-BRAF mutated CRCs, and novel therapies are needed. ERAS-007 novel, potent, orally bioavailable inhibitor ERK. combination plus EGFR (EC) approved for the treatment pts mCRC; however, only 20% experience an objective response. alone or EC showed...